Qbt1 Task 5
QBT1 task 5 Final paper Dec 20 2012
Vickie Anderson
WGU
QBT1 task 5 Final paper Dec 20 2012
Possibly the most imperative public health challenge for the United States today is the obesity epidemic the population has. This obesity epidemic, is linked to an array of costly and debilitating health consequences. The widespread challenge of obesity and the health problems and concerns that go with that is an American public health problem. FDA’s approval of two new medications that can help to decrease some of the obesity , decrease some of the chronic diseases associated with obesity, and decrease the costs associated with obesity. This essay will be addressing these pertinent problems and will prove that the new FDA drugs approved for weight loss will help American’s with weight loss that will decrease obesity, decrease chronic illnesses that are associated with obesity and decrease health care costs. Prevention of obesity along with investing in research is necessary for us to see a change in the obesity epidemic (Hammond, 2012). Research suggests that decreasing obesity will decrease the costs of health care, decrease chronic illnesses associated with obesity. Total obesity costs would be much more reduced, along with the cost for other conditions caused by excess weight in our population (Finkelstein, Trogdon, Cohen & Dietz, 2009). Research suggests that the newest FDA approved diet pills will benefit Americans by decreasing obesity, decreasing chronic diseases associated with obesity and decreasing health care costs.
Research shows that newest FDA approved diet pills Qysimia, and Blviq (lorcaserin), are helping to decrease obesity in the American population that were taking these medications. The new diet drugs approved by FDA will benefit Americans by decreasing obesity rates in the American population. With two-thirds of all our population being obese or overweight or and the related cost of health costs, FDA was under pressure to
Vickie Anderson
WGU
QBT1 task 5 Final paper Dec 20 2012
Possibly the most imperative public health challenge for the United States today is the obesity epidemic the population has. This obesity epidemic, is linked to an array of costly and debilitating health consequences. The widespread challenge of obesity and the health problems and concerns that go with that is an American public health problem. FDA’s approval of two new medications that can help to decrease some of the obesity , decrease some of the chronic diseases associated with obesity, and decrease the costs associated with obesity. This essay will be addressing these pertinent problems and will prove that the new FDA drugs approved for weight loss will help American’s with weight loss that will decrease obesity, decrease chronic illnesses that are associated with obesity and decrease health care costs. Prevention of obesity along with investing in research is necessary for us to see a change in the obesity epidemic (Hammond, 2012). Research suggests that decreasing obesity will decrease the costs of health care, decrease chronic illnesses associated with obesity. Total obesity costs would be much more reduced, along with the cost for other conditions caused by excess weight in our population (Finkelstein, Trogdon, Cohen & Dietz, 2009). Research suggests that the newest FDA approved diet pills will benefit Americans by decreasing obesity, decreasing chronic diseases associated with obesity and decreasing health care costs.
Research shows that newest FDA approved diet pills Qysimia, and Blviq (lorcaserin), are helping to decrease obesity in the American population that were taking these medications. The new diet drugs approved by FDA will benefit Americans by decreasing obesity rates in the American population. With two-thirds of all our population being obese or overweight or and the related cost of health costs, FDA was under pressure to
References: Berkrot, B., & Yukhananov, H. (2012). Fda oks first obesity drug in 13 years. Retrieved from http://www.reuters.com/article/2012/06/27/us-arena-obesity-idUSBRE85Q1AA20120627 CDC CDC. (2012, August 13). Cdc. Retrieved from http://www.cdc.gov/obesity/data/adult.html Combs, S FDA. (2012). Retrieved from website: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM312391.pdf Finkelstein, E., Trogdon, J., Cohen, J., & Dietz, W Hammond, R. A. (2012). Obesity, prevention, and healthcare costs. Retrieved from http://www.brookings.edu/research/papers/2012/05/04-health-care-hammond Ogden, C Park, A. (2012, June 28). Retrieved from http://healthland.time.com/2012/06/28/belviq-5-things-you-need-to-know-about-the-new-diet-pill/ Park, A Yao, S. (2012, June 27). Fda. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm